Trevi Therapeutics, Inc.

Trevi Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing therapies for patients with chronic cough conditions. Their primary focus is on Haduvio (oral nalbuphine ER), which targets the central and peripheral cough reflex arc. The company aims to improve the quality of life for patients suffering from serious chronic coughs, including those with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). With a strong leadership team and ongoing clinical trials, Trevi is committed to advancing treatments that address unmet medical needs in respiratory health.